Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25410283 | 0.98 | GSK3A (0.39) | GSK3AGSK3BKMT2AHTTL3MBTL1 | |
| SCHEMBL23181019 | 0.85 | BRD4 (0.34) | GSK3AGSK3BL3MBTL1LMNA | |
| SCHEMBL783280 | 0.80 | CCR9 (0.39) | L3MBTL1ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL17420468 | 0.79 | DPP4 (0.41) | KMT2AHTTKDM4EALDH1A1MAPT | |
| SCHEMBL2614384 | 0.75 | HTT (0.52) | KMT2AHTTL3MBTL1TDP1KDM4E | |
| SCHEMBL7161255 | 0.74 | CA2 (0.38) | GSK3AGSK3BTDP1KDM4EALDH1A1 | |
| SCHEMBL7052353 | 0.74 | L3MBTL1 (0.38) | KMT2AHTTL3MBTL1TDP1KDM4E | |
| SCHEMBL1000302 | 0.74 | TYR (0.45) | KMT2AHTTL3MBTL1TDP1KDM4E | |
| SCHEMBL21483640 | 0.74 | P2RX3 (0.39) | KMT2AHTTL3MBTL1TDP1KDM4E | |
| SCHEMBL12333052 | 0.72 | GSK3A (0.42) | GSK3AGSK3BL3MBTL1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | claimed |
| US-6245817-B1 | NEUROPEPTIDE Y | BAYER CORPORATION | 2001-06-12 | — | — | US | claimed |
| JP-2000510870-A | — | — | 2000-08-22 | — | — | JP | claimed |
| US-5939462-A | ADMINISTERING ALKOXY AND -THIOALKOXYAMIDE COMPOSITIONS TO MAMMALS TO TREAT DISORDERS SUCH AS OBESITY THAT ARE MEDIATED BY NEUROPEPTIDE Y (?NPY?) | BAYER CORPORATION (US) | 1999-08-17 | — | — | US | claimed |
| EP-0927166-A1 | AMIDES AS NPY5 RECEPTOR ANTAGONISTS | Bayer Corporation (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998035944-A1 | AMIDES AS NPY5 RECEPTOR ANTAGONISTS | BAYER CORPORATION (US) | 1998-08-20 | — | — | WO | claimed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023105303-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | KASHIV BIOSCIENCES, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230146125-A1 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | AJAX THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | NIHON NOHYAKU CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| US-20220313672-A1 | A PHARMACEUTICAL COMPOSITION OF S1PR MODULATORS | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2022-10-06 | — | — | US | disclosed |
| WO-2021262587-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2021-12-30 | — | — | WO | disclosed |
| US-6495125-B2 | MAY BE USED IN HAIR CARE, TEXTILE CARE, COSMETICS, ORAL CARE FORMULATIONS, SKIN, NAIL, LAUNDRY, ACNE CARE FORMULATIONS | THE PROCTER & GAMBLE COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020012639-A1 | May be used in hair care, textile care, cosmetics, oral care formulations, skin, nail, laundry, acne care formulations | PROCTER & GAMBLE COMPANY, THE | 2002-01-31 | — | — | US | disclosed |
| US-6245817-B1 | NEUROPEPTIDE Y | BAYER CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-5939462-A | ADMINISTERING ALKOXY AND -THIOALKOXYAMIDE COMPOSITIONS TO MAMMALS TO TREAT DISORDERS SUCH AS OBESITY THAT ARE MEDIATED BY NEUROPEPTIDE Y (?NPY?) | BAYER CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0927166-A1 | AMIDES AS NPY5 RECEPTOR ANTAGONISTS | Bayer Corporation (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998035944-A1 | AMIDES AS NPY5 RECEPTOR ANTAGONISTS | BAYER CORPORATION (US) | 1998-08-20 | — | — | WO | disclosed |
| CN-1034715-A | N-cyanogen methyl-2-pyridinone insecticides | DOW CHEMICAL CO (US) | 1989-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | GSK3A 1229/4885GSK3B 1023/4885KMT2A 3581/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | GSK3A 1229/4885GSK3B 1023/4885KMT2A 3581/4885 |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | BROX, CYP51A1, TBCD | GSK3A 1545/4885GSK3B 1309/4885KMT2A 2894/4885 |
| US-20220313672-A1 | A PHARMACEUTICAL COMPOSITION OF S1PR MODULATORS | S1PR1, S1PR2, S1PR3 | GSK3A 1109/4885GSK3B 1010/4885KMT2A 4291/4885 |
| US-20020012639-A1 | May be used in hair care, textile care, cosmetics, oral care formulations, skin, nail, laundry, acne care formulations | SCLY, TST, SRR | GSK3A 3091/4885GSK3B 2720/4885KMT2A 4181/4885 |
| US-20230146125-A1 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | GSK3A 1150/4885GSK3B 973/4885KMT2A 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.